Skip to content

Cyclosporine A in Cardiac Arrest

CYclosporine A in Non-shockable Out-of-hospital Cardiac Arrest ResUScitation

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01595958
Acronym
CYRUS
Enrollment
796
Registered
2012-05-10
Start date
2010-06-30
Completion date
2013-03-31
Last updated
2025-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Shockable Out of Hospital Cardiac Arrest

Keywords

Cardiac arrest, heart arrest, cyclosporine A, post cardiac arrest syndrome, protective agent, multiple organ failure, mitochondrial permeability transition pore, mitochondria, cardio-pulmonary resuscitation, cardioprotection, ischemia reperfusion, postconditioning

Brief summary

The investigators hypothesised that cyclosporine A administration at the onset of cardiopulmonary resuscitation, by inhibiting the mitochondrial permeability transition pore, could prevent the post cardiac arrest syndrome and improve outcomes.

Interventions

DRUGCyclosporine A

Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation

usual care of cardiac arrest

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* Witnessed out-of-hospital cardiac arrest * Non shockable cardiac rhythm

Exclusion criteria

* Evidence of trauma * Evidence of pregnancy * Duration of no flow more than 30 minutes * Rapidly fatal underlying disease * Allergy to cyclosporin A

Design outcomes

Primary

MeasureTime frame
Sequential Organ Failure Assessment score (SOFA)At 24 hours after hospital admission

Secondary

MeasureTime frameDescription
Hospital admission with return of spontaneous circulationAt 24 hours following admission, at day 28, at hospital discharge (an average time frame of 7 days)
SurvivalAt 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)
Good cerebral outcomeAt 24 hours following admission, at day 28, and at hospital discharge (an average time frame of 7 days)Glasgow Coma Scale and Cerebral Performance Categories
All adverse eventsuntil hospital discharge (an average time frame of 7 days)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026